ARTICLES

23Nov, 2018

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Purpose:To compare the preclinical and clinical pharmacokinetic properties of paclitaxel formulated as a Cremophor-free, albumin-bound nanoparticle (ABI-007) and formulated in Cremophorethanol (Taxol). Experimental Design: ABI-007 andTaxol were giveni.v. to Harlan… […]
READ MORE

23Nov, 2018

Increased AntitumorActivity, Intratumor Paclitaxel Concentrations, and Endothelial CellTransport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel

ABI-007, an albumin-bound, 130-nm particle form of paclitaxel, was developed to avoid Cremophor/ethanol-associated toxicities in Cremophor-based paclitaxel (Taxol) and to exploit albumin receptor-mediated endothelial transport.We studied the antitumor activity, intratumoral… […]
READ MORE

23Nov, 2018

Abraxane versus Taxol for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective

Background: Abraxane and Taxol are both effective drugs for the treatment of advanced stage breast cancer. However, each agent possesses unique drug delivery characteristics with the former not requiring premedication… […]
READ MORE

23Nov, 2018

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer

Background: Abraxane (ABI-007) is a novel 130-nm, albumin-bound (nab) particle form of paclitaxel designed to utilize endogenous albumin pathways to increase intratumor concentrations of the active drug. This multicenter phase… […]
READ MORE

23Nov, 2018

Phase II trial of weekly nab (nanoparticle albuminbound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

Nanoparticle albumin-bound (nab)-paclitaxel has better efficacy and practically eliminates the risk of hypersensitivity reactions associated with solvent-based paclitaxel. We studied weekly nab-paclitaxel and gemcitabine combination in an open-label one-stage, phase… […]
READ MORE

24Nov, 2018

Albumin-bound paclitaxel (ABI007; Abraxane) in the management of basal-like breast carcinoma

We read with great interest the paper by Banerjee et al1 regarding the clinical outcome and response to chemotherapy in basal-like carcinoma of the breast. After extensive discussion of chemotherapeutics… […]
READ MORE